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Ex vivo normothermic machine perfusion (NMP) of donor kidneys prior to trans-
plantation provides a platform for direct delivery of cellular therapeutics to optimize 
organ quality prior to transplantation. Multipotent Adult Progenitor Cells (MAPC®) 
possess potent immunomodulatory properties that could minimize ischemia reperfu-
sion injury. We investigated the potential capability of MAPC cells in kidney NMP. 
Pairs (5) of human kidneys, from the same donor, were simultaneously perfused for 
7 hours. Kidneys were randomly allocated to receive MAPC treatment or control. 
Serial samples of perfusate, urine, and tissue biopsies were taken for comparison. 
MAPC-treated kidneys demonstrated improved urine output (P = .009), decreased 
expression of injury biomarker NGAL (P = .012), improved microvascular perfusion 
on contrast-enhanced ultrasound (cortex P = .019, medulla P = .001), downregulation 
of interleukin (IL)-1β (P = .050), and upregulation of IL-10 (P < .047) and Indolamine-2, 
3-dioxygenase (P = .050). A chemotaxis model demonstrated decreased neutrophil 
recruitment when stimulated with perfusate from MAPC-treated kidneys (P < .001). 
Immunofluorescence revealed prelabeled MAPC cells in the perivascular space of 
kidneys during NMP. We report the first successful delivery of cellular therapy to a 
human kidney during NMP. Kidneys treated with MAPC cells demonstrate improve-
ment in clinically relevant parameters and injury biomarkers. This novel method of 
cell therapy delivery provides an exciting opportunity to recondition organs prior to 
transplantation.
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1  | INTRODUC TION
The UK kidney transplant waiting list stands at over 5000 pa-
tients. To bridge the gap betweensupply and demand, there has 
been increased use of donation after circulatory death (DCD) 
and extended criteria donors (ECD).1 Concerns regarding infe-
rior outcomes from DCD and ECD organs can lead to underuti-
lization of this valuable resource.2,3 DCD and ECD kidneys are 
more susceptible to ischemia reperfusion injury (IRI) manifesting 
as delayed graft function (DGF) and this can diminish long-term 
graft-survival.4,5 IRI is the result of hypoxia followed by resto-
ration of blood flow leading to microvascular dysfunction, inflam-
mation, immune activation, and tissue injury.6 As the transplant 
community becomes increasingly reliant on marginal donors, 
new therapeutic approaches to reduce IRI and optimize utiliza-
tion of kidneys are leading to a greater focus on improving organ 
preservation.
Normothermic machine perfusion (NMP) is a method of organ 
preservation that facilitates restoration of cellular metabolism, re-
viving the organ ex vivo to resume normal physiological functions.7 
Over the last few years, a number of NMP techniques and com-
mercially available devices have been adopted into clinical prac-
tice for kidney, heart, liver, and lung transplantation.8–10 Kidney 
NMP was first described in 2008.11 In this system, a pediatric car-
diopulmonary bypass machine and membrane oxygenator perfuse 
an ex vivo kidney with oxygenated red blood cells suspended in 
crystalloid at 37oC.12 A UK multicenter phase III randomized con-
trolled trial (RCT) is currently underway investigating its potential 
to minimize DGF.13
NMP provides a unique opportunity to deliver organ-di-
rected, reconditioning therapies in an isolated platform to a 
metabolically active organ.14 This could be transformative, facil-
itating direct delivery of cell therapies and reducing off-target, 
systemic effects in recipients. A recent study described the use 
of perfusion technology to preserve a liver for up to 1 week, pro-
viding a long potential therapeutic window for optimization and 
reconditioning.15
Multipotent adult progenitor cells (MAPC) are adult, bone-mar-
row derived, mesenchymal origin, stromal cells.16 MAPC cells rep-
resent an attractive “off-the-shelf,” nonimmunogenic cell therapy 
option as they lack major histocompatibility complex (MHC) Class II, 
or costimulatory molecules (CD80, CD86, and CD40) and have low 
expression of MHC Class I.17 MAPC cells release anti-inflammatory, 
immunomodulatory and pro-tolerogenic cytokines thereby limiting 
infiltration and proliferation of pathogenic immune cells.18,19 In the 
transplant setting, a rat heterotopic heart transplant model demon-
strated allogeneic MAPC cells could successfully replace standard 
pharmacological immunosuppression to maintain long-term graft 
survival.20
There have also been a number of successful clinical trials har-
nessing the immunomodulatory potential of MAPC treatment for 
graft vs host disease,21 acute respiratory distress syndrome,22 myo-
cardial infarction,23 and an ongoing phase III clinical trial in ischemic 
stroke.24 In 2015, the first successful use of allogeneic MAPC ther-
apy in human liver transplantation was also reported.25 The recipi-
ent's leucocyte population displayed diminished immune activation 
and a pro-tolerogenic profile.
MAPCs and mesenchymal stromal cells (MSC) are inherently 
very similar. MSCs were also originally isolated from adult bone 
marrow. MSC culture and expansion characteristics differ from 
MAPCs resulting in phenotypically different populations; however, 
they maintain a very similar mechanism of action.26 There has been 
a successful RCT investigating autologous MSC therapy vs standard 
induction immunosuppression (basiliximab) in live donor kidney 
transplantation. Recipients who received MSC therapy were more 
likely to recover renal function faster, had decreased rates of re-
jection, less opportunistic infections, and better renal function at 1 
year.27
However, this has not translated into widespread use of 
MAPC/MSC therapy in kidney transplantation. One of the main 
hurdles preventing widespread translation is successful delivery 
of the cells to the required organ.28 A number of animal models 
have explored the possibility of delivering a cell therapy during 
ex vivo NMP.29–31 To date, there have been no reported studies 
successfully administering a cell therapy to a human organ during 
ex vivo perfusion.
Our study aims to investigate the possible benefit of delivering 
MAPC cell therapy directly to marginal human kidneys in a preclin-
ical NMP model.
2  | MATERIAL S AND METHODS
2.1 | Ethics
Local research ethics committee approval for the use of human 
donor kidneys declined for transplantation was granted (16/
NE/0230). Currently ~ 15% of kidneys retrieved from organ donors 
across the United Kingdom are deemed unsuitable for transplant 
and can be offered for research purposes. Consent for recruitment 
was obtained from the donor's next of kin by specialist nurses in 
organ donation. Allocation of kidneys to this research project was 
overseen by National Health Services Blood & Transplant's Research 
Innovation and Novel Technologies Advisory Group (RINTAG).
Blood and Transplant (NHSBT). The views 
expressed are those of the authors and not 
necessarily those of the National Health 
Services.
K E Y W O R D S
cellular transplantation (nonislet), ischemia reperfusion injury (IRI), kidney (allograft) function/ 
dysfunction, kidney transplantation/ nephrology, organ perfusion and preservation, 
regenerative medicine, stem cells, tissue injury and repair, translational research/ science
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2.2 | Human kidney normothermic 
machine perfusion
On arrival at our center kidneys were surgically prepared on ice. 
The renal artery was cannulated to facilitate connection to the 
NMP circuit. The ureter was also cannulated so urine output could 
be measured and sampled. Kidney pairs were perfused simultane-
ous for 7 hours with an oxygenated red-cell-based perfusate at a 
mean temperature of 36.5°C and mean arterial pressure of 75 mm 
Hg, according to published protocols.32 The volume of perfusate in 
the circuit was kept constant by matching the urine output with a 
crystalloid solution via continuous infusion. All physiological param-
eters accessible during NMP were recorded and analyzed including: 
perfusate blood gas analysis, biochemical analysis, urine production, 
and flow rate and scored according to the validated “quality assess-
ment tool”.33 The kidney histopathology pre- and postperfusion was 
assessed by a consultant histopathologist (Figure S2D).
2.3 | MAPC treatment
The MAPC cells used in this study were obtained in collaboration 
with Athersys Inc (Cleveland, OH). The MAPC cells were research-
grade MultiStem® cultures isolated from human bone marrow with 
consent from a single healthy donor as previously described.34 The 
MAPC cells were confirmed to express phenotypic markers,35 be of 
>95% purity,36 and were fluorescently labeled with cytoplasmic dye 
CellTracker Red CMPTX (ThermoFisher,Waltham, MA).
For MAPC treatment of kidneys during NMP, following 60 min-
utes of perfusion, the right or left kidney was randomly allocated to a 
prescribed MAPC dose (50 × 106 cells). Immediately prior to infusion 
the MAPC cryovial aliquots were gently thawed in a water bath at 
37°C and for delivery cells were resuspended in 10 mL of perfusate. 
This was infused via a 3-way tap on the arterial cannula (Figure S3). 
Control kidneys simply received a 10 mL bolus of crystalloid. The 
cell dose was extrapolated from phase II/III clinical trials of systemic 
MAPC therapy taking into account the average weight of a human 
kidney and volume of circulating perfusion fluid.29
MAPC cells viability was evaluated using a AnnexinV/Propidium 
Iodide flow cytometry assay and revealed 90.9% viability immedi-
ately after thawing prior to infusion into the NMP circuit. To gauge 
potency, a T cell proliferation assay demonstrated MAPCs had im-
munomodulatory capability immediately upon thawing at various 
MAPC:peripheral blood mononuclear cells ratio (Figure S2E&F).
2.4 | Contrast-enhanced ultrasound
Contrast-enhanced ultrasound (CEUS) was performed during NMP. 
This technique utilizes microbubbles of inert gas (sulfur hexafluor-
ide in a phospholipid shell) to increase ultrasound signal return. 
Each bubble is approximately 2-3 μm in diameter, allowing it to 
pass through the capillary bed but not the interstitium. CEUS has 
made it possible to assess the distribution of perfusion at a micro-
circulation level.37 We have previously described this technique on 
porcine kidneys on a cold perfusion circuit.38 To investigate tissue 
perfusion CEUS on kidneys pre- and post-MAPC infusion. CEUS was 
performed using a Philips EPIQ7 Ultrasound machine. During NMP 
CEUS recordings were taken at 60 minutes (before MAPC infusion) 
and 4 hours later. Microflow imaging designed to detect blood flow 
within the small vessels at high resolution with minimal artefact was 
also performed using the Philips EPIQ7 machine. Detailed methodol-
ogy of this technique is included in the Data S1.
2.5 | ELISA
Commercially available sandwich ELISA kits (R&D Systems, 
Minneapolis, MN) measured interleukin (IL)-8 (DY208-05) in perfu-
sate and kidney injury marker 1, KIM-1 (DY1750B) and neutrophil 
gelatinase-associated lipocalin, NGAL (DY1757) in urine according 
to manufacturer's instructions.
2.6 | Mesoscale Discovery™ Multiplex
To facilitate the measurement of multiple proteins of interest in 1 
assay, a custom electrochemiluminescent Mesoscale Discovery™ 
(MSD) Multiplex was performed on perfusate samples to quantify 
cytokine expression. The 10-plex panel includes IL-1β, IL-1α, IL-2, 
IL-6, IL-10, IL-17, tumor necrosis factor alpha (TNF-α), macrophage 
inflammatory protein 1 (MIP-1), interferon gamma (IFNγ), and IL-8. 
These assays were performed according to manufacturer's in-
structions alongside technical support from an experienced MSD 
technician.
2.7 | High performance liquid chromatography
Protein was precipitated with 1:10 perchloric acid 60%; samples 
were centrifuged, filtered and, then, analyzed by high performance 
liquid chromatography (HPLC) to quantify kynurenine and trypto-
phan as described.39 Culture supernatants and perfusate were acidi-
fied with sodium acetate, pH = 4, to give a final concentration of 
15 mM.
2.8 | In vitro endothelial cell line perfusate 
stimulation model
An immortalized endothelial cell line (human microvascular endothe-
lial cell line [HMEC]-1 cells, ATCC) was used to investigate the impact 
of the perfusate secretome on endothelial function. The perfusate 
from the NMP series was centrifuged at 1500 G for 10 minutes at 
4°C and the acellular portion reserved. HMEC-1 cells were cultured 
to confluence and were treated with the acellular perfusate diluted 
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in modified MCDB131 media. In chamber slides, cells were stimu-
lated with 25 µL of acellular perfusate to evaluate protein expres-
sion using immunohistochemistry. In 6-well plates, HMEC-1 cells 
were stimulated with 250 µL of acellular perfusate to evaluate gene 
expression using reverse transcription polymerase chain reaction 
(RT-qPCR). In both situations, cells were stimulated for 4 hours. RNA 
extraction was performed on-column using Qiagen RNeasy Plus 
Mini-kit as per manufacturer's instructions. cDNA synthesis was car-
ried out using the Tetro cDNA synthesis kit. RNA sequence quanti-
fication was carried out using TaqMan RT-qPCR on a StepOnePlus™ 
Real-Time PCR System. The following primers were used; ICAM1 
TaqMan Hs00164932_m1, S1PR1TaqMan Hs00173499_m1, and 
GAPDH TaqMan Hs02786624_g1 as a housekeeping gene.
2.9 | Mouse intraperitoneal chemotaxis assay
All animal experiments were performed in accordance with the Home 
Office regulations (PPL60/4521). Eight-week-old female BALB/c mice 
received an intraperitoneal injection of 0.5 mL of crystalloid (Ringer's 
lactate), control, or MAPC perfusate (n = 5 mice per group). An ad-
ditional 5 mice were not injected. Mice were euthanized after 6 hours 
treatment and 8 mL of phosphate buffered saline (PBS)-EDTA was in-
jected into peritoneal cavity for lavage. A midline incision was made 
and lavage fluid collected. Lavage samples were centrifuged at 500 g 
for 5 minutes, the supernatant discarded and re-suspended in 100 µL 
of FACS buffer. For cell characterization the suspension was incubated 
at 4°C for 1 hour with antibodies for Ly6g-APC (Biolegend 127613, San 
Diego, CA) and CD45-PE (Biolegend 304007) to identify neutrophils 
and leucocytes, respectively. Analysis was performed on Accuri Flow 
Cytometer at 14 μL/min, recording 1 000 000 events. Results were 
analyzed using Flow Jo software.
2.10 | MAPC tracking in kidney tissue
MAPC cells were prelabeled with CellTracker CMPTX Red fluorescent 
dye (CT24552, ThermoFisher) facilitating cell tracking to evaluate par-
titioning and engraftment within the kidney. Core biopsies were taken 
at time 0, 1 hour, 4 hours after cell infusion and wedge biopsies at the 
end of perfusion. Samples were fixed in formalin and stored as paraffin 
embedded blocks. These were subsequently cut into 4 µM sections for 
fluorescence microscopy imaging using a Zeiss Axioimager.
2.11 | Immunofluorescence co-localization
Cut sections of perfused kidneys were de-waxed for 10 minutes in 
Xylene. The sections were rehydrated through graded ethanol (99%, 
90%, and 70%) then antigen retrieval in pressure cooker with 1.5 L 
of Tris/EDTA for 2 minutes. Blocking was performed with 10% goat 
serum, 100 μL/slide for 30 minutes at room temperature. Blocking 
buffer was removed and incubated with 100 μL of primary antibody 
at 4°C overnight (S1PR1, ThermoFisher Scientific PA1-1040, 1:50; 
CD31, Abcam, ab182981, 1:2000; Aquaporin-1 Abcam ab168387, 
1:100). Following wash the relevant secondary antibody (anti-rab-
bit Cy5 ThermoFisher Scientific 1:100; anti-rabbit FITC, Abcam, 
ab97050 1:200, anti-rabbit Dylight550, Immunoreagents 1:100) was 
added and incubated for 1 hour at room temperature. 0.1% Sudan 
Black B in 70% EtOH was used to quench tissue auto-fluorescence. 
Coverslips were mounted with Vectashield Antifade Mounting me-
dium with DAPI (Vectorlabs). Fluorescent imaging was performed 
using a Zeiss Axioimager or for high resolution Leica SP8 UV AOBS 
within 2 weeks of staining. Images were processed and analyzed 
using Zen, LAS X, or Fiji software.
2.12 | Statistical analysis
Continuous variables are reported as mean ± standard error of mean 
where appropriate. Data were assessed for normality, t tests, or analy-
sis of variance (ANOVA) were then applied as appropriate. A 2-sided 
paired t-test was used comparing variables between control and 
MAPC-treated kidney pairs from the same donor. The majority of ex-
periments represent n = 5 pairs of kidneys; however, the CEUS experi-
ments represent only n = 3. If another treatment group was included a 
1-way ANOVA with a Dunnett's posthoc multiple comparisons correc-
tion for continuous data was used. When recording multiple variables 
over time from the same kidney a repeated measures 2-way ANOVA 
with appropriate matching was used with Sidak's posthoc test for mul-
tiple comparisons. P values of less than .05 were deemed statistically 
significant. Analyses were performed using GraphPad Prism 8.0.
3  | RESULTS
3.1 | Kidneys included in preclinical series
Five pairs of kidneys (n = 10) were included in the study (Table 1). 
The donors included represent a heterogeneous cohort with ages 
ranging from 52 to 77 years, but all were from either DCD donors or 
had characteristics consistent with ECD status. Cold ischemic times 
were significantly extended due to the delays inherent in a kidney 
being offered for research only purposes. All kidneys pairs were 
deemed untransplantable due to a suspicion regarding nonrenal ma-
lignancy identified at retrieval.
3.2 | Establishing feasibility of cell therapy delivery 
during kidney NMP
3.2.1 | Renal physiology
Serial measurements of physiological parameters were recorded 
during NMP. Perfusate samples were analyzed in real time to assess 
adequate oxygenation, metabolic requirements, and biochemical 
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parameters and compared between the kidney pairs; this demon-
strated equivalent organ physiology associated with MAPC cell infu-
sion. For physiological parameters such as, potassium, lactate, renal 
blood flow, and renal resistance, the kidneys were well matched 
throughout the 7-hour perfusion timeline (Figure 1A-D).
During NMP the ureter of the kidney was cannulated. In the kid-
neys treated with MAPC cells, there was significantly higher urine 
output compared to control kidneys, P = .009 (Figure 1E).
3.2.2 | Kidney injury biomarkers
NGAL and KIM-1 represent promising biomarkers in acute kidney 
injury or transplantation research.40 During NMP we can analyze 
these biomarkers to evaluate reconditioning. We assessed urinary 
KIM-1 and NGAL concentration over time and compared treatment 
groups. This demonstrated that MAPC-treated kidneys showed 
a significantly lower concentration of NGAL P = .012 (Figure 1F). 
Concentrations of urinary KIM-1 were matched between both treat-
ment groups throughout perfusion (Figure S1A).
We also investigated if MAPC therapy had an effect on flavin 
mononucleotide (FMN) concentration. FMN has emerged as a prom-
ising biomarker of organ viability during liver ex vivo perfusion. 
Increased FMN measured the perfusate is a marker of mitochondrial 
complex 1 injury.41 There was a nonsignificant reduction in FMN 
production in MAPC-treated kidneys (Figure S1B).
3.2.3 | Ex vivo ultrasound
To determine if the administration of a MAPC cell bolus was associ-
ated with any effects on the renal microvasculature we performed 
a number of imaging studies using ultrasound. Microflow imaging 
(MFI) Doppler ultrasound provided high resolution detail on blood 
flow within small vessels. This revealed there was restored blood 
flow within the renal medulla 4 hours after MAPC cell infusion 
(Figure 1G, indicated by white arrow). The same effect was not seen 
in control kidneys.
Alongside MFI, CEUS was performed before MAPC cell infusion 
and 4 hours later. CEUS provides a quantifiable assessment of micro-
vascular perfusion and demonstrated a significant improvement in 
both cortical and medullary perfusion after 4 hours of MAPC treat-
ment during NMP, compared to the control kidneys, P = .019 and 
P = .001, respectively (Figure 1H & I).
3.3 | Evaluating the immunomodulatory potential of 
MAPC therapy during NMP
3.3.1 | Cytokine profiling
MAPC cells are reported to mediate their immunomodulatory ca-
pacity through increasing anti-inflammatory cytokines and down 
regulating pro-inflammatory cytokines. A panel of cytokines were 
measured at serial time points during perfusion (time 0, 1 hour, 
2 hours, 4 hours, and 7 hours) to evaluate this phenomenon dur-
ing NMP. This panel revealed MAPC-treated kidneys had a sig-
nificant reduction in IL-1β, P = .050 (Figure 2A). There was also a 
significant increase in anti-inflammatory cytokine IL-10, P = .047 
(Figure 2B). Alongside this was a nonsignificant reduction in other 
pro-inflammatory cytokines; IL-6, IL-1α, IL-17, and IL-8 but his 
was not the case for all cytokines; TNFα, MIP-1β, IL-2, and IFNγ. 
(Figure S1 C).
3.3.2 | Indolamine-2, 3-dioxygenase activity
MAPC cells are reported to regulate T cells via indolamine-2,3-diox-
ygenase (IDO) (19). Cells expressing IDO catabolize tryptophan (Trp) 
to suppress effector T cells and activate Foxp3-lineage regulatory 
TA B L E  1   Clinical characteristics of donor kidney pairs included in study
Kidney pair
Age 
(years)
Donor 
type
Reason for 
decline CIT (time) Vascular anatomy Weight (g) KDPI QAS score @1 hr
HLA
mismatch
Pair 1 60 DBD nonrenal 
malignancy
20 h 35 m L – 1A 1V
R – 1A 2V
L – 270 g
R – 260 g
1.79
(D4)
L - 3
R - 3
211
Pair 2 52 DCD nonrenal 
malignancy
29 h 35 m L – 1A 1V
R – 2A 1V
L – 235 g
R – 220 g
0.98
(D2)
L - 2
R - 2
221
Pair 3 62 DBD nonrenal 
malignancy
36 h 20 m L – 2A 1V
R – 1A 1V
L – 285 g
R – 288 g
1.61
(D4)
L - 5
R - 5
111
Pair 4 76 DBD nonrenal 
malignancy
35 h 38 m L – 1A 1V
R – 1A 1V
L – 199 g
R - 235g
2.12
(D4)
L - 1
R - 1
211
Pair 5 77 DCD nonrenal 
malignancy
13 h 06 m L – 1A 1V
R – 1A 1V
L – 331 g
R – 249 g
1.96
(D4)
L - 1
R - 1
110
Note: A, artery; CIT, cold ischemic time; DBD, donation after brainstem death; DCD, donation after circulatory death; KDPI, Kidney Donor Profile 
Index (UK); L, left kidney; MAPC, Multipotent Adult Progenitor Cells; QAS, Quality Assessment Score (composite measure of kidney quality 
composed of renal blood flow, urine output, and macroscopic perfusion appearance; R, right kidneys; V, vein.
Scored 1-5 (best = 1, worst = 5, suitable for transplant if score ≤ 3). HLA Mismatch grade between MAPC cells and kidney.
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CD4 T cells (Tregs).42 IDO activity was assessed by measuring Trp 
and the catabolite kynurenine (Kyn) in the perfusate using HPLC. 
This revealed that MAPC-treated kidneys had significantly higher 
IDO activity (elevated Kyn:Trp ratio) following 7 hours of perfusion 
when compared to IDO activity in paired control kidneys, P = .050 
(Figure 2C).
3.3.3 | MAPC perfusate secretome effect on HMEC-
1 endothelial cell line model
An in-vitro endothelial cell line model was established to bet-
ter understand the impact of MAPC perfusate secretome on the 
endothelium and microvascular integrity following reperfusion. 
Samples of perfusate taken after 7 hours of NMP were added 
to HMEC-1 cells in culture. ICAM-1 (activation status) and S1PR1 
(microvascular barrier integrity) expression was analyzed in the 
HMEC-1 cells in response to perfusate from pairs of kidneys (con-
trol perfusate vs MAPC perfusate) (Figure 2D-G). ICAM-1 pro-
tein expression was significantly increased in the control group, 
P < .001. However, in the MAPC-treated group this upregulation 
was not as marked, P = .022. In contrast, S1PR1 gene and pro-
tein expression in HMEC-1 cells was downregulated by control 
perfusate; however, MAPC perfusate maintained S1PR1 gene 
expression at unstimulated levels, P = .032; and increased pro-
tein expression when compared with control perfusate, P < .001. 
This preservation of S1PR1 protein was also seen on immuno-
fluorescence in the tissue of NMP perfused kidneys, P = .030 
(Figure 2H-J).
3.3.4 | MAPC secretome effect on mouse 
intraperitoneal chemotaxis assay
To evaluate if the MAPC secretome in the perfusate during NMP 
had an impact on leucocyte chemotaxis we used a small animal 
model. Samples of acellular perfusate were injected intraperito-
neally to mice. There were 4 treatment groups, each containing 5 
mice, as described in the methods section. Six hours after injec-
tion the intraperitoneal space was lavaged to harvest the immune 
cell infiltrate, which was analyzed using flow cytometry (Figure 
S1D-F). Control perfusate led to a significant increase in perito-
neal Ly6G + neutrophils compared to crystalloid injections alone, 
P < .001. This increase was not seen in perfusate from MAPC-
treated kidneys, (Figure 2K-L) indicating reduced inflammatory 
chemotaxis.
3.4 | Determining the physical distribution of NMP 
administered MAPC cells
MAPC cells were prelabeled with a red fluorescent dye in order 
to understand cell fate following intra-arterial delivery during 
NMP. To achieve this, following 7 hours of perfusion, anatomical 
regions of interest sampled from the cortex, medulla, artery, and 
collecting system of the kidney and visualized using fluorescent 
immunohistochemistry and confocal microscopy. Nuclear counter-
staining was with DAPI (blue). Additional staining for endothelial cell 
marker (CD31 - green) and a proximal tubular epithelial cell marker 
(Aquaporin-1) was performed for morphological co-localization. 
This revealed the majority of MAPC cells were in the glomeruli in 
sections of cortex and around the peritubular space in the sections 
of medulla (Figure 3A-E).
The tissues sections only account for the fate of MAPC cells 
within the kidney; there was also a proportion of MAPC cells that 
remained circulating within the perfusate. A cell filter was added to 
the perfusion circuit after 7 hours of NMP to evaluate this. These 
cells were subsequently analyzed on flow cytometry, (Figure S2A). 
This revealed a small population of red positive cells alongside a 
separate population of unlabeled cells, assumed to be passenger 
leucocytes. A viability assay revealed the mean proportion of cir-
culating live MAPC cells to be 21%. In contrast, the passenger leu-
cocyte population had 44% viability. The proportion of passenger 
leucocytes resident in the kidney tissue was assessed and revealed 
no significant difference between MAPC and control kidneys 
(Figure S2B,C).
F I G U R E  1   Establishing the feasibility of MAPC therapy during kidney NMP. Panels A-D depict real-time physiological parameters 
measured during the NMP timeline. Panel (A) electrolyte balance (potassium), (B) cellular metabolism (lactate), (C) renal blood flow and 
(D) intrarenal resistance recorded throughout the perfusion timeline. Panel E depicts the impact of MAPC treatment on urine output; 
n = 5pairs, paired t-test, **P < .01 (MAPC-treated kidneys mean urine output 1436mL ± 281 vs control 960mL ± 189). Panel F demonstrates 
MAPC treatment effect on a biomarker of kidney injury NGAL concentration measured at serial time points during perfusion, repeated-
measures 2-way ANOVA with Sidak's multiple comparison's post-hoc test, *P < .05 **P < .01 (MAPC-treated mean NGAL concentration 
7196pg/ml ± 379 vs control 12400pg/ml ± 1014 at 7 hours). Panel G demonstrates still images taken from one pair of kidneys recorded 
during Doppler Ultrasound MicroFlow Imaging. Blue colouring represents overlaid Doppler signal from blood flow within microvasculature. 
Image A – Control kidney after 60 minutes of NMP, Image B – the same control kidney scanned after 4 hours of NMP. Image C MAPC-
treated kidney after 60 minutes of NMP before MAPC cell infusion, Image D- the same kidney scanned 4 hours after MAPC cell infusion 
demonstrating new blood flow within the medullary pyramid (white arrow). CEUS performed during NMP to assess the impact of MAPC cell 
therapy on microvascular perfusion in ischemic kidneys. Panel H depicts objective AUC analysis of cortex perfusion comparing Contrast-
enhanced ultrasound scans performed at 60 minutes and 4 hours. Panel I depicts AUC analysis of medulla perfusion comparing CEUS scans 
performed at 60 minutes and 4 hours. n = 3, paired t-test, *P < .05 **<0.01 (MAPC-treated mean cortex perfusion AUC 0.97 ± 0.13 vs control 
0.34 ± 0.11). ANOVA, analysis of variance; AUC, area under the curve; CEUS, contrast-enhanced ultrasound; MAPC, Multipotent Adult 
Progenitor Cells; NGAL, neutrophil gelatinase-associated lipocalin
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4  | DISCUSSION
MAPC therapy has demonstrated significant promise in treating a 
number of clinical conditions associated with inflammation and is-
chemia.22–24,43 Clinical trials have demonstrated MAPC cells have a 
robust safety profile. Therefore, the translation of MAPC therapy to 
minimize ischemia reperfusion injury in kidney transplantation rep-
resents a promising avenue for further exploration. Here we have 
described the first reported series of human kidneys infused with a 
cellular therapy using normothermic machine perfusion.
Kidneys treated with MAPC therapy demonstrated an improve-
ment in physiological parameters and biomarkers of kidney injury. 
A B C
D F G
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A higher volume of urine output and lower urinary NGAL during NMP 
has previously been correlated with improved clinical outcomes fol-
lowing transplantation.33,44 Improving these key parameters with 
MAPC treatment is suggestive of less tissue damage and improved 
cellular metabolism. We have also demonstrated a significant im-
provement in microvascular perfusion during NMP using CEUS. The 
improved blood flow seen in MAPC-treated kidneys could be medi-
ated by PGE2 or IDO, both potent vasodilators, which are reported 
to be part of the MAPC cell secretome in pro-inflammatory environ-
ments.45 Interestingly, the global renal blood flow was unchanged 
but vasodilation of the microvasculature seems to result in improved 
tissue perfusion and reestablishment of homeostasis as evidenced 
by increased urine output and reduction in NGAL.
Cytokine profiling revealed that MAPC therapy during kidney 
NMP was associated with an anti-inflammatory, pro-tolerogenic 
cytokine profile. This included decreased expression of IL-1β, a 
pro-inflammatory cytokine associated with endothelial activation. 
Decreased IL-1β expression during ex vivo lung perfusion correlates 
with improved survival following lung transplantation.46 There was 
also upregulation of pro-tolerogenic, anti-inflammatory IL-10 and 
this was accompanied by increased IDO activity. MAPC cells mod-
ulating differential cytokine expression in perfusate may be key in 
their potential role of minimizing IRI.
Tracking MAPC cells after NMP delivery revealed cells could be 
found throughout the kidney. The distribution was similar to that 
described when MSCs were delivered to pig kidneys.31 Previous 
studies demonstrated MAPC cells have a powerful ability to home 
to hypoxic endothelium where they migrate into tissue, taking up 
residence within the perivascular space.47–49 Indeed, in a preclinical 
study of acute myocardial infarction the cells actively migrated into 
the ischemic myocardium following transarterial delivery.50 This may 
be mirrored in our NMP model – MAPC cells are homing to hypoxic 
areas within the kidney where they take temporary residence. In this 
micro-environment, the cells release an anti-inflammatory secre-
tome, which is having beneficial effects; increased blood flow, im-
proved urine output, and reduced tubular injury. The proportion of 
circulating nonviable MAPC cells may also have a mechanistic role. 
Previous studies have demonstrated that apoptotic MSCs induce 
a significant immunosuppressive response mediated by recipient 
phagocytes.51
NMP provides a platform for direct delivery of MAPC therapy, 
overcoming the limitations of systemic delivery where cell therapies 
can get trapped in the lungs or liver of recipients, reducing deliv-
ery to target sites.28,52 During NMP, the pro-inflammatory ischemic 
kidney provides a microenvironment to prime MAPC cells, licensing 
them to take on the desired immunomodulatory phenotype. This 
direct delivery platform that effectively primes cells could provide 
the solution to a previous significant barrier in MSC/MAPC therapy 
translation.53
The timing of MAPC/MSC delivery has been demonstrated as a 
key factor effecting therapy efficacy and NMP facilitates early de-
livery of cells prior to implantation. Timing of MSC infusion relative 
to the organ transplant plays an important role in the potency of 
the cell's immunomodulatory effect.54 One study demonstrated, in 
an animal model of semi-allogeneic heart transplantation, that the 
systemic infusion of MSCs into the recipient prior to transplantation 
conferred a stronger pro-tolerogenic therapeutic effect than if the 
infusion was given postoperatively.55 This has since been replicated 
in a number of settings, including kidney, and confirmed that deliv-
ery of cells posttransplant can result in graft inflammation, whereas 
pretransplant infusion resulted in interaction with myeloid popula-
tions and localization to lymphoid organs leading to expansion of 
pre-tolerogenic Tregs and diminished inflammation.56–58
However, there are a number of limitations in this study. NMP 
as an experimental system is limited in its ability to measure the 
posttransplantation effectiveness of a therapy. These issues 
F I G U R E  2   Evaluating the immunomodulatory capability of MAPC therapy during kidney NMP. Panels A and B depict significant results 
from custom Mesoscale Discovery™ panel analyzing perfusate cytokine concentrations comparing control (blue) with MAPC-treated (red) 
NMP kidneys. Results are expressed as the mean fold change calculated relative to time zero. Panel A demonstrates a significant decreased 
expression of cytokine IL-1β, paired t test, n = 5pairs, *P < .05 (MAPC-treated mean fold change 6.9 ± 2.1 vs control 26.8 ± 7.7). Panel B 
demonstrates a significant increase IL-10 in MAPC group, paired t test, n = 5 pairs, *P < .05 (MAPC-treated mean fold change 949.4 ± 288.6 
vs control 252.9 ± 71.3). Panel C compares IDO activity in paired kidneys after 7 hours of NMP, paired t test, n = 5 pairs, *P < .05 (MAPC-
treated K/T ratio 0.34 ± 0.02 vs control 0.29 ± 0.03). Panels D and E depict qPCR results from perfusate stimulated HMEC-1 cells (control 
kidneys vs MAPC treated). Panel D demonstrates ICAM-1 gene expression, paired t test, n = 5 pairs, p = ns (MAPC treated mean fold change 
on qPCR 9.6 ± 3.1 vs 6.5 ± 0.9). Panel E S1PR1 gene expression, paired t test, *P < .05 (MAPC treated mean fold change on qPCR −4.9 ± 1.7 
vs control 0.6 ± 0.6). Panels F and G depict perfusate stimulated HMEC-1 cells immunohistochemistry staining for ICAM-1 and SIPR1 protein 
expression (control vs MAPC treated). Graph F demonstrates comparison of ICAM-1 protein expression between treatment groups (MAPC 
treated 23.9 ± 3.3 vs control perfusate 37.3 ± 9.2). Graph G demonstrates comparison of S1PR1 protein expression between treatment 
groups (MAPC treated 76.5 ± 4.7 vs control perfusate 57.6 ± 4.9). Analyzed with 1-way ANOVA and Tukey's test posthoc analysis, *P < .05, 
**P < .01, ***P < .001. Panels H and I depict S1PR1 staining visualized using fluorescence microscopy on kidney biopsies taken during 
NMP, blue stain is DAPI, red is S1PR1. Panel J demonstrates a significant upregulation of S1PR1 protein expression as quantified by mean 
fluorescence intensity, paired t test, n = 5 pairs, *P < .05 (MAPC treated 0.11 ± 0.01 vs control 0.18 ± 0.02). Panels K and L demonstrate 
results from mouse intraperitoneal chemotaxis experiments. Panel K depicts typical flow cytometry scatter plots examining staining for 
Ly6G + neutrophils isolated from mouse peritoneal lavage for different treatment groups. Panel L depicts the mean number of Ly6G + cells 
isolated from lavage samples demonstrating neutrophil recruitment with MAPC perfusate compared to control perfusate, paired t test, n = 5 
pairs, **P < .01 (MAPC 2990 ± 506 neutrophils vs control mice 8849 ± 1675 neutrophils). ANOVA, analysis of variance; HMEC-1, human 
microvascular endothelial cell line 1; IDO, indolamine 2, 3 dioxygenase; IL, interleukin; MAPC, Multipotent Adult Progenitor Cells; NMP, 
normothermic machine perfusion; qPCR, quantitative polymerase chain reaction
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would need to be addressed in further studies. Additionally, we 
cannot determine the fate and persistence of the MAPC popula-
tion after transplantation of the kidney. Other animal studies in-
vestigating systemic MSC therapy have demonstrated cells are no 
longer traceable in the recipient at 21 days, indeed the majority 
are lost from the system by 72 hours.43 There is also debate about 
the necessity of MSC or MAPC cell engraftment to support their 
therapeutic actions as this may be modulated through phagocy-
tosis of the cells by recipient monocyte/macrophage populations 
which contribute to subsequent immunomodulation.59 Also, the 
immunogenicity of MAPC cells in the NMP setting needs inves-
tigated. It has been previously demonstrated that the in vitro im-
munosuppressive activity of MAPC cells was independent of MHC 
matching.17 Reassuringly, in other clinical circumstances where 
allogeneic MAPC cells have been used there was no evidence of 
development of new anti-HLA antibodies in unsensitized patients 
treated after myocardial infarction23 or in 18 immunosuppressed 
bone marrow transplantation patients.21
4.1 | Conclusion
This is the first reported series of cell therapy successfully delivered 
directly to human donor kidneys in an isolated ex vivo perfusion plat-
form. Kidneys treated with MAPC cells during NMP demonstrate im-
provement in clinically relevant parameters and a reduction in injury 
F I G U R E  3   Determining MAPC cell fate and physical distribution following delivery during kidney NMP. MAPC cells were prelabeled 
with a red cytoplasmic fluorescent dye (CellTracker Red CMPTX, ThermoFisher) to facilitate tracking of the cells through the kidney 
following 7 hours of perfusion. The red labeled cells are the MAPC cells as noted by white arrows. Counter nuclear staining is in blue with 
DAPI. The green staining is endothelial marker CD31 and highlights the kidneys vasculature. The pink staining is Aquaporin 1 a marker 
for proximal tubular cells. Panels A and B are sections taken from the kidney cortex after 6 hours of MAPC treatment during NMP. These 
represent typical confocal microscopy images from kidneys treated with MAPC cells. The white letter (G) identifies the glomerulus. Panel C 
is a typical section taken from the kidney's medulla; vessels identified by the CD31 green stain are identified by the green (V). Panel D is a 
high magnification image taken of three MAPC cells that are resident in the interstitium next to a peritubular capillary. Panel E depicts the 
confocal images of a blood vessel from the renal cortex with a MAPC cell in the lumen and cells that have mobilized out of the vessel into the 
nearby tissue. MAPC, Multipotent Adult Progenitor Cells; NMP, normothermic machine perfusion
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and pro-inflammatory biomarkers. This effect may be mediated by 
changes to circulating cytokines or through secreted soluble anti-in-
flammatory mediators. NMP represents a novel cell therapy delivery 
system. This represents a paradigm shift, providing an exciting oppor-
tunity to directly treat organs prior to transplantation to minimize IRI. 
A future clinical trial evaluating this modality of delivery could result 
in the transplantation of otherwise discarded organs, thereby reduc-
ing the transplant waiting list and offering hope to patients with renal 
failure.
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